Surgery Partners rejects Bain Capital's take-private offer
Surgery Partners' shares fell more than 13% to $20.10 in premarket trading.
A special committee of independent directors has concluded that the best path forward for the company and its stockholders was to continue operating as an independent publicly traded company, Surgery Partners said.
Bain Capital, which in January offered to acquire all the remaining shares of the company it does not already own for $25.75 apiece, has a 38.97% stake in Surgery Partners, according to LSEG data.
The private equity firm did not immediately respond to Reuters' request for comment.
Surgery Partners had previously attracted acquisition interest from private equity firm TPG (TPG.O), opens new tab and healthcare giant UnitedHealth Group (UNH.N), opens new tab, according to a Bloomberg News report in August 2024.
The surgical facility operator plans to host an investor day in the second half of 2025 to present its strategy and outlook.
The company also reiterated its annual revenue forecast of $3.3 billion to $3.45 billion, compared with analysts' average estimate of $3.38 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
22 minutes ago
- Reuters
Huntington Bancshares signs $1.9 billion deal for rival Veritex in Texas push
July 14 (Reuters) - U.S. regional lender Huntington Bancshares (HBAN.O), opens new tab will buy Texas-based smaller rival Veritex Holdings (VBTX.O), opens new tab in a $1.9 billion all-stock deal, as it looks to expand its presence in the state that is fast emerging as a major financial hub. Shares of Columbus, Ohio-based Huntington Bancshares, a regional bank with $210 billion in assets, fell 1.8%, while Veritex jumped 20% after the companies announced the news. Wall Street is expecting dealmaking activity among U.S. banks to pick up in the second half of 2025 as recession fears fade and regulators become more open to consolidation. Huntington will issue 1.95 shares for each outstanding share of Veritex, valuing the company at $33.91 per share. The offer price represents a 23.5% premium to Veritex's last close. "This combination supports our ambitions and reflects our long-term commitment to the state of Texas, one of the most dynamic and fastest-growing economies in the country," said Huntington CEO Steve Steinour. In recent years, Huntington has extended its geographic footprint, mainly in North and South Carolina and Texas. Business-friendly policies of Texas as well as its growing tech and energy sectors, have attracted companies looking to tap into its long-term growth potential. Texas GDP hit a record $2.7 trillion in 2024. Truist Securities analyst Brian Foran said the Veritex acquisition may signal more deals ahead for Huntington. Huntington CEO Steinour told analysts the deal will be a "springboard" to drive faster growth in Texas, where Veritex operates over 30 branches, with $13 billion in assets. Following the deal, Texas will rank as Huntington's third largest deposit state, with a $15 billion loan portfolio. Veritex will help accelerate commercial lending and capital markets opportunities across commercial real estate, corporate middle market and regional banking, Huntington said. The transaction, set to close early in the fourth quarter of 2025, is expected to be "modestly accretive to Huntington's earnings per share," the bank said. Veritex CEO Malcolm Holland will join Huntington in a non-executive role as chairman of Texas. Separately, Huntington projected a 13% jump in second-quarter profit to 34 cents per share, underpinned by higher interest income. Evercore and Commerce Street Capital advised Huntington, while Keefe, Bruyette & Woods advised Veritex.
Daily Mail
30 minutes ago
- Daily Mail
Nick Saban 'isn't done coaching' and could rock college football world by leaving ESPN to return to sideline
Nick Saban's retirement may already be winding down. The seven-time national champion coach at Louisiana State and Alabama is rumored to be eying a return to the sidelines a couple of years after his final season in Tuscaloosa. 'A very much in-the-know person that I have a lot of respect for and have spent a lot of time around, and just really, really admire – they seem to think Nick Saban is not done coaching,' former Crimson Tide quarterback Greg McIlroy sad on Monday's 'Mac and Cube' show in Birmingham. 'He's pretty adamant that he thinks Nick Saban will be coaching again.' Asked for his source, McIlroy opted against revealing too much but did emphasize this person is definitely a high-level college football insider. 'If it wasn't someone notable, I would never say a word,' McIlroy said. 'He is of firm belief that Nick Saban will coach in college football again.' Saban, now a co-host on ESPN's College GameDay, was replaced at Alabama by former Washington head coach Kalen DeBoer, who went 9-4 in his first season at the helm. It's not clear if Saban is eying a return to the Crimson Tide or another program, but the College Football Hall of Famer would likely have many suitors if he decided to leave his analyst position with ESPN. One school to keep an eye on could be Arkansas, which is just 30-31 under head coach Sam Pittman. The Razorbacks athletic department does have deep pockets, thanks to donors like former Arkansas football player and current Dallas Cowboys owner Jerry Jones, Tyson Foods chairman John Tyson, and the Walton family, owners of Wal-Mart. What's more, Jones and Saban do have a relationship, but it's unclear if that could be used to sway the decorated coach to Fayetteville. And just last year, ESPN reported that Arkansas was able to sign former national-champion basketball coach John Calipari to a $42.5 million deal thanks to the looming presence of boosters like Jones. In December, CNBC ranked Arkansas as the 18th-ranked NCAA athletic department in terms of value, which was estimated at $776 million.
Reuters
37 minutes ago
- Reuters
Becton to merge unit with Waters in $17.5 billion deal
July 14 (Reuters) - Lab equipment maker Waters Corp (WAT.N), opens new tab will merge with rival Becton, Dickinson and Company's (BDX.N), opens new tab Biosciences & Diagnostic Solutions unit in a $17.5 billion deal, the companies said, creating a larger entity focused on high-volume medical testing. The deal announced on Monday is structured as a so-called Reverse Morris Trust, which allows a company to avoid a big tax bill by spinning off a unit that it wants to divest while simultaneously merging it with another company. The eye-popping deal value signifies the amount of stock that BD shareholders will have in the combined company - about 39.2% - and the $4 billion cash distribution that BD will receive at closing. Becton's biosciences and diagnostic solutions unit makes products used to detect infectious diseases and cancers. The company has been looking to divest the unit to deepen focus on its core business of medical devices. Funding for life sciences and microbiology research has been under pressure in recent years, impacting the performance of BD's biosciences business. Meanwhile, sale of medical devices remained robust post pandemic due to the increased demand for outpatient and other surgeries. The merger doubles Waters' addressable market to $40 billion, enhances recurring revenue streams and accelerates expansion into areas such as bioseparations, bioanalytical characterization and multiplex diagnostics, Waters CEO Udit Batra said. The market reaction, however, was opposite, with Waters' shares falling 5.3% premarket following the announcement. Becton's stock was marginally down. Leerink analysts said investors will likely not view the deal as attractive in the near term, given the higher exposure to microbiology amid recent funding cuts. As part of the deal, which is expected to close in the first quarter of 2026, Waters will assume about $4 billion in incremental debt.
